Insider Selling: Albany Molecular Research SVP Unloads 2,500 Shares of Stock (AMRI)
Albany Molecular Research (NASDAQ:AMRI) SVP Lori M. Henderson unloaded 2,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.56, for a total transaction of $48,900.00. Following the transaction, the senior vice president now directly owns 42,063 shares in the company, valued at approximately $822,752. The sale was disclosed in a document filed with the SEC, which is available at this link.
Albany Molecular Research (NASDAQ:AMRI) traded up 0.10% during mid-day trading on Wednesday, hitting $19.33. 335,433 shares of the company’s stock traded hands. Albany Molecular Research has a 52 week low of $9.71 and a 52 week high of $22.30. The stock has a 50-day moving average of $19.72 and a 200-day moving average of $17.89. The company has a market cap of $610.0 million and a price-to-earnings ratio of 38.78.
Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. Analysts expect that Albany Molecular Research will post $0.91 EPS for the current fiscal year.
A number of analysts have recently weighed in on AMRI shares. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 12th. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.